The Ministry of Health, Labor and Welfare (MHLW) on November 29 proposed a more stringent application of the current 40% entry price rule for first oral generics towards the FY2024 drug pricing reform.Under the current rule, first oral generics are…
COMMENTARY
Japan to See Arrival of 1st Treatment for HFpEF, Will Entresto Meet Unmet Medical Needs?
Novartis Pharma’s chronic heart failure treatment Entresto (sacubitril valsartan sodium hydrate) is about to make its Japan debut, with its label allowing its use for heart failure with preserved left ventricular ejection fraction (HFpEF). With no drug currently approved for…
To read the full story
Related Article
- Hypertension OK Now in Hand, Novartis Expanding Entresto Pitch to GPs with Superior Efficacy over ARBs
November 1, 2021
- Personalized Approach Needed for HFpEF Treatment with Entresto: Professor
August 28, 2020
- As Entresto Hits Japan Market, Novartis Poised to Tap All Channels to Push Global Blockbuster
August 26, 2020
- Japan Approves Entresto, 4 Other Novartis Meds, Rybelsus, 1st Humira Biosimilar and More
June 30, 2020
- Eyes Turn to SGLT2 Inhibitors after Entresto’s Narrow Miss in HFpEF
October 16, 2019
COMMENTARY
- Key Figures in Next Drug Pricing Reform Now All in Place, In What Direction Will They Go for Pro-Innovation Drive?
November 15, 2023
- Predicting Clinical, Financial Impact of Hemophilia Gene Therapy in Japan
November 7, 2023
- Reform Proposal Signals Perception Gap between Industry, Govt on Purpose of Market Expansion Re-Pricing
October 31, 2023
- With 2nd Strategy Penned, Can Japan Play Catch-Up with US & Europe in SaMD Push?
October 3, 2023
- Hopes to Nix Budget Ceiling Dashed, How Will Industry Get Its Message Across to Govt?
September 4, 2023
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
A member of the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry on November 13…
A health ministry study group on pharmaceutical regulations on October 13 roughly agreed on a reform plan for Japanese regulatory…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…